Stock Events

Stock Events

ProQR Therapeutics N.V 

$1.6
41
+$0.02+1.59% Today

Statistics

Day High
1.63
Day Low
1.54
52W High
3.05
52W Low
1.37
Volume
3,951,090
Avg. Volume
-
Mkt Cap
171.8M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30JulExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.15
-0.13
-0.11
-0.09
Expected EPS
-0.1446618996
Actual EPS
N/A

Financials

-146.98%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
39.33MRevenue
-57.81MNet Income

Analyst Ratings

4Average Price Target
The highest estimate is 4.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PRQR. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Ionis Pharmaceuticals
IONS
Mkt Cap12.49B
Ionis Pharmaceuticals, Inc. specializes in RNA-targeted drug discovery and development, similar to ProQR's focus on RNA therapies for genetic disorders.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.71B
Alnylam Pharmaceuticals, Inc. is a leader in RNAi therapeutics, directly competing in the RNA-based treatment space that ProQR operates within.
Sarepta Therapeutics
SRPT
Mkt Cap1.77B
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for rare diseases, closely aligning with ProQR's mission.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.45B
BioMarin Pharmaceutical Inc. develops and commercializes innovative biopharmaceuticals for rare diseases and medical conditions, a market that ProQR also targets.
PTC Therapeutics
PTCT
Mkt Cap5.71B
PTC Therapeutics, Inc. engages in the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders, competing in ProQR's therapeutic area.
Ultragenyx Pharmaceutical
RARE
Mkt Cap2.3B
Ultragenyx Pharmaceutical Inc. is focused on the development of novel products for rare and ultra-rare diseases, including genetic disorders, which is a direct competition to ProQR's focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap110.28B
Vertex Pharmaceuticals Incorporated is known for its work in treating cystic fibrosis, a genetic disorder, which may overlap with ProQR's target diseases.
CRISPR Therapeutics
CRSP
Mkt Cap4.86B
CRISPR Therapeutics AG specializes in gene editing, a next-generation approach to treating genetic disorders, potentially competing with ProQR's RNA-based therapies.
Editas Medicine
EDIT
Mkt Cap270.22M
Editas Medicine, Inc. is involved in developing gene editing technologies to treat genetically driven diseases, offering an alternative to ProQR's approach.
Intellia Therapeutics
NTLA
Mkt Cap1.76B
Intellia Therapeutics, Inc. is a leading gene editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, competing in the genetic disease space with ProQR.

About

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Show more...
CEO
Mr. Daniel Anton de Boer
Employees
166
Country
Netherlands
ISIN
NL0010872495

Listings

MX
MX
PRQRN.MX
STU
DE
0PQ.STU
MU
DE
0PQ.MU
F
DE
0PQ.F

0 Comments

Share your thoughts

FAQ

What is ProQR Therapeutics N.V stock price today?▼
The current price of PRQR is $1.6 USD — it has increased by +1.59% in the past 24 hours. Watch ProQR Therapeutics N.V stock price performance more closely on the chart.
What is ProQR Therapeutics N.V stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange ProQR Therapeutics N.V stocks are traded under the ticker PRQR.
Is ProQR Therapeutics N.V stock price growing?▼
PRQR stock has risen by +11.54% compared to the previous week, the month change is a +7.05% rise, over the last year ProQR Therapeutics N.V has showed a -6.18% decrease.
What is ProQR Therapeutics N.V market cap?▼
Today ProQR Therapeutics N.V has the market capitalization of 171.8M
When is the next ProQR Therapeutics N.V earnings date?▼
ProQR Therapeutics N.V is going to release the next earnings report on July 30, 2026.
What were ProQR Therapeutics N.V earnings last quarter?▼
PRQR earnings for the last quarter are -0.15 USD per share, whereas the estimation was -0.14 USD resulting in a -8.6% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is ProQR Therapeutics N.V revenue for the last year?▼
ProQR Therapeutics N.V revenue for the last year amounts to 39.33M USD.
What is ProQR Therapeutics N.V net income for the last year?▼
PRQR net income for the last year is -57.81M USD.
How many employees does ProQR Therapeutics N.V have?▼
As of May 27, 2026, the company has 166 employees.
In which sector is ProQR Therapeutics N.V located?▼
ProQR Therapeutics N.V operates in the Health & Wellness sector.
When did ProQR Therapeutics N.V complete a stock split?▼
ProQR Therapeutics N.V has not had any recent stock splits.
Where is ProQR Therapeutics N.V headquartered?▼
ProQR Therapeutics N.V is headquartered in Leiden, Netherlands.